Market Research Logo

Global Bronchodilators Market 2017-2021

Global Bronchodilators Market 2017-2021

About Bronchodilators

Bronchodilators are a type of medication, which make breathing easy by relaxing the muscles in the lungs and widening the airways (bronchi). They are used to treat the breathing problems, majorly asthma and COPD. Short-acting bronchodilators are the first-line therapy, which is widely used in bronchodilators. These agents have a short-term (2-4 hours) duration of action and therefore require multiple dosages. Whereas, long-acting bronchodilators, which are introduced recently, have an extended period of action. They reduce the process of multiple dosages. Therefore, they are more effective than the short-term bronchodilators. Technavio’s analysts forecast the global bronchodilators market to grow at a CAGR of 4.78% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global bronchodilators market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Bronchodilators Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AstraZeneca
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
Other prominent vendors
  • ALK-Abello
  • Amgen
  • Array BioPharma
  • ASMACURE
  • Astellas Pharma
  • Atopix Therapeutics
  • CHIESI Farmaceutici
  • Dynavax Technologies
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin
  • MediciNova
  • Mitsubishi Tanabe Pharma
  • Mundipharma International
  • Nycomed Pharma
  • Oxagen
  • Pearl Therapeutics
  • Pharmaxis
  • Pulmagen Therapeutics
  • Regeneron Pharmaceuticals
  • Revalesio
  • Sanofi
  • SolAeroMed
  • Stallergenes Greer
  • sterna biologicals
  • Synairgen
  • Theron Pharmaceuticals
  • UCB Pharma
  • Verona Pharma
Market driver
  • Market potential toward mAb
  • For a full, detailed list, view our report
Market challenge
  • Increased preference for CAM
  • For a full, detailed list, view our report
Market trend
  • Innovative technologies for drug delivery
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Releases

Technavio Announces the Publication of its Research Report – Global Bronchodilators Market 2017-2021

Technavio recognizes the following companies as the key players in the global bronchodilators market: AstraZeneca, Boehringer Ingelheim, F. Hoffmann-La Roche, and GlaxoSmithKline.

Other Prominent Vendors in the market are: ALK-Abello, Amgen, Array BioPharma, ASMACURE, Astellas Pharma, Atopix Therapeutics, CHIESI Farmaceutici, Dynavax Technologies, Kissei Pharmaceutical, Kyowa Hakko Kirin, MediciNova, Mitsubishi Tanabe Pharma, Mundipharma International, Nycomed Pharma, Oxagen, Pearl Therapeutics, Pharmaxis, Pulmagen Therapeutics, Regeneron Pharmaceuticals, Revalesio, Sanofi, SolAeroMed, Stallergenes Greer, sterna biologicals, Synairgen, Theron Pharmaceuticals, UCB Pharma, and Verona Pharma.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Innovative technologies for drug delivery. Technological advances and innovations in the healthcare industry have resulted in the development of drugs and delivery devices as per the end-user requirement. New technologies in the development of drugs, which can be easily administered and exhibit higher efficacy are more preferred in the market. For instance, in April 2016 AstraZeneca received approval from the US FDA for Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol for patients suffering from COPD. The drug is the company's first product to use its patented Co-Suspension Technology.”

According to the report, one of the major drivers for this market is Market potential toward mAb. Monoclonal antibodies are expected to boost the market growth for the treatment of asthma, owing to the development of target specific drugs. mAb blocking immunoglobulin E (IgE) are specifically approved for the treatment of allergic asthma. Also, the mAb against immunoglobulin or specific cytokines, which are known to be important in the initiation or persistence of asthmatic inflammation are being developed.

Further, the report states that one of the major factors hindering the growth of this market is Increased preference for CAM. People who have asthma tend to adopt alternative methods of treatment instead of pharmacologic treatments. According to a recent report, in the US, more than 15% of the population suffer from allergic diseases including allergic asthma, allergic rhinitis, and atopic dermatitis, and more than 40% of people used CAM for these conditions. The usage of CAM for allergic conditions is higher in some European countries, because of efficacy, safety, and low cost of some therapies. The lack of a well-designed clinical trial for these treatments makes it difficult to determine the safety and effectiveness over pharmacotherapies.

Companies Mentioned

AstraZeneca, Boehringer Ingelheim, F. Hoffmann-La Roche, GlaxoSmithKline, ALK-Abello, Amgen, Array BioPharma, ASMACURE, Astellas Pharma, Atopix Therapeutics, CHIESI Farmaceutici, Dynavax Technologies, Kissei Pharmaceutical, Kyowa Hakko Kirin, MediciNova, Mitsubishi Tanabe Pharma, Mundipharma International, Nycomed Pharma, Oxagen, Pearl Therapeutics, Pharmaxis, Pulmagen Therapeutics, Regeneron Pharmaceuticals, Revalesio, Sanofi, SolAeroMed, Stallergenes Greer, sterna biologicals, Synairgen, Theron Pharmaceuticals, UCB Pharma, and Verona Pharma.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Market outline
      • Table Types of bronchodilators
  • Pipeline analysis
    • Table Pipeline landscape
    • Table Pipeline analysis
  • Market landscape
    • Market overview
      • Table Usage of bronchodilators
      • Table Global bronchodilators market 2016-2021 ($ millions)
      • Table Opportunity analysis in global bronchodilators market
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by drug class
    • Anticholinergic bronchodilators
      • Table Global anticholinergic bronchodilators market 2016-2021 ($ millions)
    • Adrenergic bronchodilators
      • Table Global adrenergic bronchodilators market 2016-2021 ($ millions)
    • Bronchodilator combinations
      • Table Global bronchodilator combinations market 2016-2021 ($ millions)
    • Methylxanthines
      • Table Global methylxanthines bronchodilators market 2016-2021 ($ millions)
  • Geographical segmentation
    • Table Global bronchodilators market based on geography 2016 and 2021 (%)
    • Table Bronchodilators market revenue by geography 2016-2021 ($ millions)
    • Bronchodilators market in Americas
      • Table Market scenario in Americas
      • Table Bronchodilators market in Americas 2016-2021 ($ millions)
    • Bronchodilators market in EMEA
      • Table Market scenario in EMEA
      • Table Bronchodilators market in EMEA 2016-2021 ($ millions)
    • Bronchodilators market in APAC
      • Table Market scenario in APAC
      • Table Bronchodilators market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Recent approvals in mAb for bronchodilators market
      • Table Drugs expected to get approval in forecast period
      • Table Recent approvals in bronchodilators market
    • Market challenges
  • Market trends
    • Innovative technologies for drug delivery
    • Growing usage of home healthcare devices
    • Strong product pipeline
      • Table Drug approvals in COPD drugs market in past three years
      • Table COPD drug molecules in the stage of registration
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global bronchodilators market 2016
      • Table Strategic success factors of companies in global bronchodilators market
  • Key vendor analysis
    • AstraZeneca
      • Table AstraZeneca: Strength assessment
      • Table AstraZeneca: Strategy assessment
      • Table AstraZeneca: Opportunity assessment
    • Boehringer Ingelheim
      • Table Boehringer Ingelheim: Strength assessment
      • Table Boehringer Ingelheim: Strategy assessment
      • Table Boehringer Ingelheim: Opportunity assessment
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: Strength assessment
      • Table F. Hoffmann-La Roche: Strategy assessment
      • Table F. Hoffmann-La Roche: Opportunity assessment
    • GlaxoSmithKline
      • Table GlaxoSmithKline: Strength assessment
      • Table GlaxoSmithKline: Strategy assessment
      • Table GlaxoSmithKline: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report